WO1996010014A1 - Derives aldehydes utilises comme inhibiteurs de protease d'upsteine - Google Patents

Derives aldehydes utilises comme inhibiteurs de protease d'upsteine Download PDF

Info

Publication number
WO1996010014A1
WO1996010014A1 PCT/JP1995/001933 JP9501933W WO9610014A1 WO 1996010014 A1 WO1996010014 A1 WO 1996010014A1 JP 9501933 W JP9501933 W JP 9501933W WO 9610014 A1 WO9610014 A1 WO 9610014A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
stands
substituted
groups
Prior art date
Application number
PCT/JP1995/001933
Other languages
English (en)
Inventor
Takashi Sohda
Yukio Fujisawa
Tsuneo Yasuma
Junji Mizoguchi
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Priority to AU35341/95A priority Critical patent/AU3534195A/en
Priority to EP95932228A priority patent/EP0783489A1/fr
Publication of WO1996010014A1 publication Critical patent/WO1996010014A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to novel acylaminoaldehyde derivatives. More specifically, it relates to novel acylaminoaldehyde derivatives showing strong inhibitory action against cysteine protease such as cathepsin L, cathepsin B and calpain.
  • cysteine protease such as cathepsin L, cathepsin B and calpain.
  • cysteine protease such as cathepsin , cathepsin B or calpain (calcium-dependent neutral protease: CANP)
  • CANP calcium-dependent neutral protease
  • cathepsin B inhibitors are useful as therapeutic agents of arthrosis such as rheumatoid arthritis or as anti-inflammatory agents.
  • cathepsin B is deeply associated with the process of cancer metastasis because it participates in destruction of collagen, which is an important step of metastasis of cancer.
  • a cathepsin B inhibitory agent is considered to be effective for suppressing the propagation of tumor cells and preventing cancer metastasis.
  • cysteine protease such as calpain or cathepsin B
  • cysteine protease is considered to play a role in the initial process, for example disappearance of Z line, through decomposition of muscular fiber protein (Shinkei Naika Chiryo, Vol. 5, p.209, 1988).
  • an inhibitory agent of cysteine protease such as calpain or cathepsin B is considered to be effective as a therapeutic agent of myodystrophy, muscular atrophy or the like.
  • a protein called amyloid On senile plaques specifically observed in brains of patients suffering from Alzheimer's disease, a protein called amyloid is deposited, and this amyloid has been known to occur by the decomposition of amyloid protein precursor (APP) .
  • APP amyloid protein precursor
  • cathepsin B inhibitory agent is considered to be effective of prophylaxis and therapy of Alzheimer's disease.
  • an anti-cathepsin B antibody which suppresses the action of cathepsin B, shows anti-virus activity (Japanese published unexamined patent application No. H5-105635/1993) .
  • anti-virus activity is expected also in a cathepsin B inhibitory agent .
  • a cysteine protease inhibitory agent especially an epoxysuccinic acid derivative that inhibits cathepsin B, is capable of inhibiting the activity of protease participating in processing of the immunological fragment of an antibody and suppresses the production of a specific antibody.
  • rhematoid arthritis various autoimmune diseases caused by reaction of immune system with the molecule of its own, which are exemplified by rhematoid arthritis, multiple sclerosis, myathemia gravis, insulin dependent diabetes mellitus (type I diabetes mellitus), inflammatory bowl diseases, systemic lupus erythematosus, glomerulonephritis, autoimmune hemolytic anemia, Hashimoto's disease, idiopathic ulcerative colitis, primary biliary cirrhosis, idiopathic thrombocytopenic purpura, sympathetic ophthalmia, permicious anemia, Sjogren's syndrome and Goodpasture's syndrome (Japanese published unexamined patent application No. H6-336428/1994) .
  • cysteine protease inhibitory agents epoxysuccinic derivatives such as E-64 (Agricultural and Biological Chemistry, Vol.42, p.523, 1978) and CA-074 (FEBS Lett., Vol.280, p.307, 1991), or chloromethyl ketone derivatives (Journal of
  • the present inventors have diligently studied aiming at the development of novel reversible cysteine protease inhibitors which are excellent in oral absorbability and cell membrane permeability. As the result, they found that ⁇ -, ⁇ - and ⁇ -acylaminoaldehyde derivatives represented by the following formula (la) are potent reversible cysteine protease inhibitors, and have completed the present invention. So far, there have been no reports at all that acylaminoaldehyde derivatives of ⁇ -, ⁇ - and ⁇ -types show cysteine protease inhibitory activity. As described above, the acylaminoaldehyde derivatives of the present invention are expected to be new therapeutic medicines of various diseases in which cysteine protease plays a role.
  • the present invention relates to: (1) a compound of the formula (la'):
  • R -Q'-NHCH-X-CHO wherein Q' stands for one or two amino acid residual groups which may be substituted; R stands for a hydrogen atom or an optionally substituted hydrocarbon or heterocyclic group; R stands for an optionally esterified carboxyl group or an acyl group; and X stands for an optionally substituted straight-chain or branched divalent hydrocarbon group having a chain length of 1 to 4 atoms as the linear moiety, or a salt thereof, (2) a compound of term (1) above, in which is one represented by the formula (I' ) :
  • R 1 , R and R independently stand for a hydrogen atom or an optionally substituted hydrocarbon or heterocyclic group;
  • R stands for an optionally esterified carboxyl group or an acyl group;
  • X stands for an optionally substituted straight-chain or branched divalent hydrocarbon group having a chain length of 1 to 4 atoms as the linear moiety; and
  • n is 0 or 1, or a salt thereof, (3) a compound of term (2) above, in which R 1 , R 2 and R are independently an optionally substituted alkyl group,
  • R , R and R 3 are independently a straight-chain or branched Cj. 6 alkyl group which may be substituted with an optionally substituted aryl group or a heterocyclic group,
  • a compound of term (2) above in which R is a straight-chain or branched alkyl group which is substituted with an aryl group or a heterocyclic group, (8) a compound of term (2) above, in which R and R are independently a straight-chain or branched C ⁇ _ 6 alkyl group, (9) a compound of term (2) above, in which the acyl group is that derived from a carboxylic acid, sulfonic acid, sulfinic acid, carbamic acid or thiocarbamic acid,
  • Q' stands for one or two amino acid residual groups which may be substituted;
  • R stands for a hydrogen atom or an optionally substituted hydrocarbon or heterocyclic group; and
  • R stands for an optionally esterified carboxyl group or an acyl group, or a salt thereof, with an acetaldehyde derivative, followed by reduction upon necessity,
  • composition which comprises a compound of the formula (la) :
  • Q stands for a direct bond or one or two a ino acid residual groups which may be substituted
  • R 1 stands for a hydrogen atom or an optionally substituted hydrocarbon or heterocyclic group
  • R stands for an optionally esterified carboxyl group or an acyl group
  • X stands for an optionally substituted straight- chain or branched divalent hydrocarbon group having a chain length of 1 to 4 atoms as the linear moiety, or a pharmaceutically acceptable salt thereof, (18) a composition of term (17) above, which is for inhibiting a cysteine protease
  • Q stands for a direct bond or one or two amino acid residual groups which may be substituted;
  • R stands for a hydrogen atom or an optionally substituted hydrocarbon or heterocyclic group;
  • R stands for an optionally esterified carboxyl group or an acyl group;
  • X stands for an optionally substituted straight- chain or branched divalent hydrocarbon group having a chain length of 1 to 4 atoms as the linear moiety, or a pharmaceutically acceptable salt thereof, and (21) use of a compound of the formula (la):
  • Q stands for a direct bond or one or two amino acid residual groups which may be substituted
  • R 1 stands for a hydrogen atom or an optionally substituted hydrocarbon or heterocyclic group
  • R stands for an optionally esterified carboxyl group or an acyl group
  • X stands for an optionally substituted straight- chain or branched divalent hydrocarbon group having a chain length of 1 to 4 atoms as the linear moiety, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament to be used as a cysteine protease inhibitor.
  • the acylaminoaldehyde derivatives in the present invention are structurally different compounds from so far known compounds having enzyme-inhibitory actions. And, among known acylaminoaldehyde derivatives such as ⁇ -, ⁇ and ⁇ -ones, no compounds possessing the inhibitory actions have been known. On the other hand, the compounds of the formulas (la') and (I') are those having a novel structure in that they have such characteristic features as showing the enzyme- inhibitory actions.
  • the constituent amino acids are of the L-configuration, unless otherwise stated.
  • their notation is in accordance with the IUPAC (International Union of Pure and Applied Chemistry)-IUB (International Union of Biochemistry) Biochemical Nomenclature, e.g. Gly for glycine, Leu for leucine and lie for isoleucine.
  • amino-protecting groups those which are known in the relevant field are employed.
  • Preferable amino-protecting groups include acetyl, benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, tert.- butoxycarbonyl, phthalyl and formyl, with preference given to benzyloxycarbonyl or tert.-butoxycarbonyl.
  • the amino acid residue for the "1 or 2 amino acid residual groups which may be substituted" shown by Q' and Q is exemplified by ⁇ -amino acids, ⁇ -amino acids and ⁇ -amino acids, which are represented by the respective formulas RCH( H 2 )COOH, H 2 NCH 2 CHRC0 2 H and H 2 NCH 2 CH 2 CHRC0 2 H (R represents a hydrogen atom or a hydrocarbon group or heterocyclic group which may be substituted), with preference given to ⁇ -amino acids.
  • the 2 amino acids may be of the same type or not, but the residue preferably consists of 2 ⁇ -amino acids.
  • the dipeptidyl residue consists of 2 amino acids of the same type (e.g., amino acid residue consisting of 2 ⁇ -amino acids)
  • the 2 amino acids may be identical or not.
  • the "hydrocarbon group which may be substituted” shown by R is exemplified by the same hydrocarbon groups as those exemplifying the "hydrocarbon group which may be substituted” shown by R , R or R below.
  • the "heterocyclic group which may be substituted” shown by R is exemplified by the same heterocyclic groups as those exemplifying the "heterocyclic group which may be substituted” shown by R 1 , R 2 or R 3 below.
  • R is exemplified by the same substituents as those for the "hydrocarbon group or heterocyclic group which may be substituted" shown by R , R or R below.
  • ⁇ -amino acid residue is exemplified by glycine and natural or non-natural L- or D- ⁇ -amino acids.
  • amino acids include glycine, ⁇ - L-amino acid and ⁇ -D-amino acid (e.g.
  • Q' may have 1 to 3 substituents at any possible positions. Such substituents are exemplified by the same substituents for the "hydrocarbon group or heterocyclic group which may be substituted" shown by R , R or R below.
  • Q' is preferably a group of the formula (Ia'-Q'):
  • R and R independently stand for a hydrogen atom or an optionally substituted hydrocarbon or heterocyclic group; and n is 0 or 1.
  • Q is preferably a group of the formula (Ia-Q):
  • R 2 and R independently stand for a hydrogen atom or an optionally substituted hydrocarbon or heterocyclic group; and m and n independently are 0 or 1.
  • saturated or unsaturated aliphatic hydrocarbon groups mention is made of, for example, the groups set forth in the following i) to v), namely, i) Ci-i o straight-chain or branched saturated aliphatic hydrocarbon groups (e.g.
  • C ⁇ _ 10 alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, tert.-butyl, pentyl, isopentyl, neopentyl, tert.-pentyl, hexyl, isohexyl, heptyl and octyl), with preference given to C,_ 6 straight-chain or branched saturated aliphatic hydrocarbon groups, ⁇ ) C 2 _ 10 straight-chain or branched unsaturated aliphatic hydrocarbon groups (e.g. C 2 .
  • alkenyl groups such as ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2- butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2- pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-hexenyl, 3-hexenyl, 2,4-hexadienyl, 5-hexenyl, 1- heptenyl and 1-octenyl, and C 2 .
  • alkynyl groups such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4- pentynyl, 1-hexynyl, 3-hexynyl, 2,4-hexadiynyl, 5- hexynyl, 1-heptynyl and 1-octynyl), with preference given to C 2 . 6 straight-chain or branched unsaturated aliphatic hydrocarbon groups, iii) C 3 . 12 saturated alicyclic hydrocarbon groups (e.g.
  • C 3 - 12 cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[3.2.2]nonyl, bicyclo[3.3.l]nonyl, bicyclo[4.2.1]nonyl and bicyclo[4.3.l]decyl) , with preference given to C 3 . 6 saturated alicyclic hydrocarbon groups, iv) C 5 . 12 unsaturated alicyclic hydrocarbon groups
  • cycloalkenyl groups such as 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2- cyclohexenyl, 3-cyclohexenyl, 1-cycloheptenyl, 2- cycloheptenyl, 3-cycloheptenyl, 2,4-cycloheptadienyl, 2-cyclopenten-l-yl, 3-cyclopenten-l-yl, 2-cyclohexen-l- yl and 3-cyclohexen-l-yl, and C 5 .
  • cycloalkadienyl groups such as 2,4-cyclopentadien-l-yl, 2,4- cyclohexadien-1-yl and 2,5-cyclohexadiene-l-yl
  • C ⁇ _ 8 saturated aliphatic hydrocarbon groups substituted with the above-mentioned saturated or unsaturated alicyclic hydrocarbon groups (e.g. C 3 . 7 cycloalkyl-C,_ 8 alkyl or C 5 .
  • cycloalkenyl-C ⁇ _ 8 alkyl more specifically, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, 2- cyclopentenylmethyl, 3-cyclopentenylmethyl, cyclohexylmethyl, 2-cyclohexenylmethyl, 3- cyclohexenylmethy1, eyelohexylethy1, eyelohexylpropyl, cycloheptylmethyl and cycloheptylethyl, for example) .
  • aryl groups mention is made of monocyclic or condensed polycyclic C 6 . aromatic cyclic hydrocarbon groups.
  • aromatic cyclic hydrocarbon groups examples include phenyl, tolyl, xylyl, biphenyl, 1- or 2- naphthyl, 1-, 2- or 9-anthryl, 1-, 2-, 3-, 4- or 9- phenanthryl, 1-, 2-, 4-, 5- or 6-azulenyl and acenaphthylenyl, and, among them, phenyl, 1-naphthyl and 2-naphthyl, for example, are preferable.
  • the "hydrocarbon group which may be substituted" shown by R , R or R may have 1 to 3 optionally chosen substituents at any possible positions.
  • substituents include aryl groups that may be substituted, cycloalkyl or cycloalkenyl groups that may be substituted, heterocyclic groups that may be substituted, carboxyl groups that may be esterified, carbamoyl groups that may be substituted, amino groups that may be substituted, hydroxyl groups that may be substituted, thiol groups that may be substituted, halogens (e.g., fluorine, chlorine, bromine, iodine) and phosphono groups that may be substituted.
  • halogens e.g., fluorine, chlorine, bromine, iodine
  • aryl group that may be substituted is exemplified by phenyl, naphthyl, anthryl, phenanthryl and acenaphthylenyl, with preference given to phenyl. 1-naphthyl and 2-naphthyl.
  • Said aryl may have 1 to 2 optionally chosen substituents at any possible positions, these substituents including a hydroxy group, alkoxy groups that may be substituted (e.g., C ⁇ _ 3 alkoxys such as methoxy, ethoxy and propoxy) , halogen atoms (e.g., fluorine, chlorine, bromine, iodine) and alkyl groups that may be substituted (e.g., C ⁇ _ 3 alkyls such as methyl, ethyl and propyl) .
  • alkoxy groups and alkyl groups may have 1 or 2 optionally chosen substituents at any possible positions, these substituents including phosphono groups that may be substituted (e.g., dimethoxyphosphoryl, diethoxyphosphoryl) .
  • cycloalkyl group that may be substituted is exemplified by C 3 . 7 cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • the kinds and number of said cycloalkyl groups that may be substituted are the same as those of the substituents for the above-described aryl group that may be substituted.
  • cycloalkenyl group that may be substituted is exemplified by C 3 . 6 cycloalkenyl groups such as cyclopropenyl, cyclobutenyl, cyclopentenyl and cyclohexenyl.
  • the kinds and number of said cycloalkenyl groups that may be substituted are the same as those of the substituents for the above- described aryl group that may be substituted.
  • heterocyclic group that may be substituted is exemplified by aromatic heterocyclic groups having at least one hetero atom selected from atoms of oxygen, sulfur and nitrogen as a ring-constituting atom (ring atom) , and saturated or unsaturated non-aromatic heterocyclic groups (aliphatic heterocyclic groups), with preference given to aromatic heterocyclic groups.
  • aromatic heterocyclic groups include aromatic monocyclic heterocyclic groups (e.g., furyl, thienyl.
  • pyrrolyl oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furazanyl, 1,2,3- thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl) and aromatic condensed heterocyclic groups (e.g., benzofuranyl, isobenzofuranyl, benzo[b_]thienyl, indolyl, isoindolyl, lH-indazolyl, benzimidazolyl, benzoxazolyl
  • Such non-aromatic heterocyclic groups include oxylanyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuryl, thiolanyl, piperizyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl and piperazynyl.
  • the substituent for said heterocyclic group that may be substituted is exemplified by alkyl groups having 1 to 3 carbon atoms (e.g., methyl, ethyl, propyl) .
  • Such carboxyls that may be esterified include lower alkoxycarbonyls (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert.-butoxycarbonyl, sec- butoxycarbonyl, pentyloxycarbonyl, isopentyloxycarbonyl, neopentyloxycarbonyl, tert.- pentyloxycarbonyl) and aryloxycarbonyls (e.g., phenoxycarbonyl, 1-naphthoxycarbonyl, benzyloxycarbonyl), with preference given to the carboxyl group, raethoxycarbonyl and ethoxycarbonyl.
  • lower alkoxycarbonyls e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert.-butoxycarbon
  • the substituent for said carbamoyl group that may be substituted is exemplified by lower (C ⁇ _ 6 ) alkyls that may be substituted (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, tert.-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl), C 3 .
  • cycloalkyl groups that may be substituted (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl), aryl groups that may be substituted (e.g., phenyl, 1- naphthyl, 2-naphthyl) and aralkyl groups that may be substituted (e.g., benzyl, phenethyl); 1 or 2 of these substituents, whether identical or not, may be present.
  • the substituent for said amino group that may be substituted is exemplified by lower (C ⁇ _ 6 ) alkyls that may be substituted (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, tert.-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl), C 3 _ 6 cycloalkyl groups that may be substituted (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl), aryl groups that may be substituted (e.g., phenyl, 1- naphthyl, 2-naphthyl) and aralkyl groups that may be substituted (e.g., benzyl, phenethyl); 1 or 2 of these substituents, whether identical or not, may be present
  • the substituent for said hydroxyl group that may be substituted is exemplified by lower (C ⁇ ) alkyls that may be substituted (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, tert.-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl), C 3 _ 6 cycloalkyl groups that may be substituted (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl), aryl groups that may be substituted (e.g., phenyl, 1- naphthyl, 2-naphthyl) and aralkyl groups that may be substituted (e.g., benzyl, phenethyl).
  • C ⁇ alkyls e.g., methyl,
  • the substituent for said thiol group that may be substituted is exemplified by lower (C,_ 6 ) alkyls that may be substituted (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, tert.-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl), C 3 .
  • cycloalkyl groups that may be substituted (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl), aryl groups that may be substituted (e.g., phenyl, 1- naphthyl, 2-naphthyl) and aralkyl groups that may be substituted (e.g., benzyl, phenethyl).
  • the substituent for said phosphono group that may be substituted is exemplified by dimethoxyphosphoryl, diethoxyphosphoryl, dipropoxyphosphoryl, diisopropoxyphosphoryl, ethylenedioxyphosphoryl, trimethylenedioxyphosphoryl and tetramethylenedioxyphosphoryl.
  • the substituent may be an aliphatic hydrocarbon group that may be substituted.
  • Such aliphatic hydrocarbon groups include the same saturated or unsaturated (preferably saturated) hydrocarbon groups as those exemplifying the "hydrocarbon group that may be substituted” shown by R 1 , R 2 or R 3 above, with preference given to alkyl groups (e.g., C ⁇ . 3 alkyls such as methyl, ethyl and propyl) .
  • the aliphatic hydrocarbon group may have 1 or 2 optionally chosen substituents at any possible positions, these substituents including phosphono groups that may be substituted (e.g., dimethoxyphosphoryl, diethoxyphosphoryl) .
  • heterocyclic group which may be substituted shown by R 1 , R 2 or R 3 , is exemplified by aromatic heterocyclic groups having at least 1 hetero atom selected from atoms of oxygen, sulfur and nitrogen as a ring-constituting atom (ring atom), and saturated or unsaturated non-aromatic heterocyclic groups (aliphatic heterocyclic groups), with preference given to aromatic heterocyclic groups.
  • aromatic heterocyclic groups are exemplified by 5- or 6-membered aromatic heterocyclic groups containing 1 or 2 atoms of nitrogen and 1 atom of sulfur or oxygen, including aromatic monocyclic heterocyclic groups (e.g. furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-oxadiazolyl, 1,2,4- oxadiazolyl, 1,3,4-oxadiazolyl, furazanyl, 1,2,3- thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, 2-, 3- or 4-pyridyl, 3- or 4-pyridazinyl, 2-, 4-, 5- or 6- pyrimidinyl, 2-pyrazinyl and triaziny
  • the aromatic heterocyclic group may condense with a 6-membered ring containing 2 or fewer atoms of nitrogen, a benzene ring, a 5-membered ring containing 1 atom of sulfur, or the like.
  • the non-aromatic heterocyclic groups include 5- to 7-membered heterocyclic groups containing one sulfur atom, nitrogen atom or oxygen atom or 5- to 6-membered heterocyclic group containing 2 to 4 nitrogen atoms, (e.g.
  • non-aromatic heterocyclic groups may be such ones as being condensed with benzene ring, a 6-membered ring containing 2 or less nitrogen atoms or a 5-membered ring containing one sulfur atom.
  • condensed non-aromatic heterocyclic groups include chromanyl, isochromanyl, indolinyl, isoindolinyl, thiochromanyl or isothiochromanyl.
  • the "heterocyclic group that may be substituted" shown by R 1 , R or R may have 1 to 3 optionally chosen substituents at any possible positions.
  • substituents include aryl groups that may be substituted, cycloalkyl or cycloalkenyl groups that may be substituted, heterocyclic groups that may be substituted, carboxyl groups that may be esterified, carbamoyl groups that may be substituted, amino groups that may be substituted, hydroxyl groups that may be substituted, thiol groups that may be substituted, halogens (e.g., fluorine, chlorine, bromine, iodine), phosphono groups that may be substituted, and aliphatic hydrocarbon groups that may be substituted.
  • fluorine chlorine, bromine, iodine
  • phosphono groups that may be substituted
  • aliphatic hydrocarbon groups that may be substituted.
  • halogens e.g., fluorine, chlorine, bromine, iodine
  • phosphono groups that may be substituted
  • aliphatic hydrocarbon groups that may be substituted are exemplified by the same ones as substituents for the "hydrocarbon group that may be substituted" shown by R , R or R above.
  • R , R or R include the above-mentioned C ⁇ . 10 alkyl, especially straight-chain or branched C ⁇ _ 6 lower alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, tert.- butyl, pentyl, isopentyl, neopentyl, tert.-pentyl, hexyl, isohexyl, 4-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl and 2-ethylbutyl) .
  • substituents for the "hydrocarbon group which may be substituted" are aryls that may be substituted (preferably phenyl etc.) and heterocyclic groups that may be substituted.
  • the "hydrocarbon group which may be substituted" shown by R , R or R is an alkyl group substituted with an aryl or heterocyclic group.
  • Said alkyl substituted with an aryl is exemplified by groups resulting from binding of a monocyclic or condensed polycyclic aromatic hydrocarbon group having 6 to 14 carbon atoms (e.g., phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl) and a lower alkyl having 1 to 6 carbon atoms (preferably C ⁇ __, alkyl) (e.g., benzyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl, 1-phenylpropyl, ⁇ -naphthylmethyl, ⁇ -naphthylethyl, ⁇ - naphthylmethyl, ⁇ -naphthylethyl) .
  • Said alkyl substituted with a heterocyclic group is exemplified by groups resulting from binding of an aromatic heterocyclic group and a lower alkyl having 1 to 6 carbon atoms (preferably C ⁇ ., alkyl group) .
  • aromatic heterocyclic groups include 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl.
  • R is preferably a straight-chain or branched C ⁇ _ 6 alkyl group which may be substituted with an aryl group or a heterocyclic group (e.g., indol-3-ylmethyl, benzyl, methyl, isopropyl, 1-naphthylmethyl etc.), more preferably a straight-chain or branched C ⁇ _ 6 alkyl group which is substituted with an aryl group or a heterocyclic group.
  • an aryl group or a heterocyclic group e.g., indol-3-ylmethyl, benzyl, methyl, isopropyl, 1-naphthylmethyl etc.
  • R 2 and R3 are preferably independently a straight- chain or branched C 6 alkyl group which may be substituted with an phenyl group (e.g., sec-butyl, benzyl, isobutyl, isopropyl etc.), more prefrably independently an unsaturated straight-chain or branched Ci. 6 alkyl group.
  • phenyl group e.g., sec-butyl, benzyl, isobutyl, isopropyl etc.
  • R 1 , R 2 and R As optionally substituted hydrocarbon groups shown by R 1 , R 2 and R , mention is made more specifically as follows: preferable examples of R include indol-3- ylmethyl, (substituted)benzyl, methyl, isopropyl and 1- naphthylmethyl; preferable examples of R 2 include sec- butyl, benzyl, isobutyl and isopropyl; preferable examples of R 3 include sec.-butyl, isobutyl and isopropyl.
  • R is indol-3-ylmethyl, benzyl, methyl, isopropyl or 1-naphthylmethyl and R 2 is sec- butyl, benzyl, isobutyl isopropyl or p- hydroxyphenylmethyl.
  • R is indol-3-ylmethyl, benzyl, methyl, isopropyl or 1-naphthylmethyl
  • R is sec- butyl, benzyl, isobutyl or isopropyl
  • R be sec.- butyl, benzyl, isobutyl or isopropyl.
  • the "acyl group" shown by R is exemplified by acyl groups derived from carbamic acids that may be substituted, thiocarbamic acids that may be substituted, carboxylic acids that may be substituted, sulfinic acids that may be substituted, sulfonic acids that may be substituted, etc., specifically those represented by the respective general formulas -CONHR 7 , -CSNHR 8 , -COR 9 , -SOR 10 , -S0 2 R 6
  • R 7 8 9 10 6 shown by R , R , R , R or R is exemplified by the same hydrocarbon groups as those exemplifying the
  • hydrocarbon group that may be substituted shown by R 1 , R 2 or R 3 above.
  • the "hydrocarbon group that may be substituted" shown by R 7, R8, R9, R10 or R6, may have 1 to 3 optionally chosen substituents at any possible positions, these substituents being exemplified by the same substituents as those defined for the "hydrocarbon group that may be substituted” shown by R , R or R above.
  • the "heterocyclic group that may be substituted” 7 8 9 10 6 shown by R , R , R , R or R is exemplified by the same heterocyclic groups as those for the "heterocyclic group that may be substituted" shown by R 1 , R 2 or R 3 above.
  • R , R , R or R may have 1 to 3 optionally chosen substituents at any possible positions, these substituents being exemplified by the same substituents as those defined for the "heterocyclic group that may be substituted" shown by
  • acyl group shown by R ,4 is exemplified by aliphatic acyl groups such as alkanoyl groups (e.g., lower alkylcarbonyl groups such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl and hexanoyl) , alkenoyl groups (e.g.
  • lower alkenylcarbonyl groups such as acryloyl, methacryloyl, crotonoyl and isocrotonoyl
  • cycloalkanecarbonyl groups e.g., cycloalkylcarbonyl groups such as cyclopropanecarbonyl, cyclobutanecarbonyl, cyclopentanecarbonyl and cyclohexanecarbonyl
  • cycloalkenylcarbonyl groups e.g., cyclopropenylcarbonyl, cyclobutenylcarbonyl, cyclopentenylcarbonyl, cyclohexenylcarbonyl
  • alkanesulfonyl groups e.g., lower alkylsulfonyl groups such as mesyl, ethanesulfonyl and propanesulfonyl
  • aromatic acyl groups such as aroyl groups (e.g., arylcarbonyl
  • the groups represented by the formula -COR are preferably represented by the formula -COR 9 (R 9 represents a hydrogen atom or an alkyl, alkenyl, aromatic hydrocarbon or aromatic heterocyclic group that may be substituted) .
  • alkyl that may be substituted is exemplified by lower (C ⁇ ) alkyls (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, tert.-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl) .
  • C ⁇ alkyls e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, tert.-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl
  • R " is exemplified by lower (C 2 . 6 ) alkenyls (e.g., ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2-pentenyl,
  • alkenyls e.g., ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2-pentenyl,
  • alkyl that may be substituted and “alkenyl that may be substituted” shown by R , may each have 1 or 2 optionally chosen substituents at any possible positions, these substituents including aryl groups that may be substituted (preferably phenyl, 1-naphthyl,
  • Such aryls may each have 1 or 2 optionally chosen substituents at any possible positions, these substituents including alkyl groups that may be substituted (e.g., C t _ 3 alkyls such as methyl, ethyl and propyl).
  • alkyl groups may each have 1 or 2 optionally chosen substituents at any possible positions, these substituents including phosphono groups that may be substituted (e.g., dimethoxyphosphoryl, diethoxyphosphoryl) .
  • the "aromatic hydrocarbon group that may be substituted" shown by R preferably includes phenyl, tolyl, xylyl, biphenyl, 1- or 2-naphthyl, 1-, 2- or 9- anthryl, 1-, 2-, 3-, 4- or 9-phenanthryl, 1-, 2-, 4-, 5- or 6-azulenyl and acenaphthylenyl, and, among them, phenyl, 1-naphthyl and 2-naphthyl, for example, are preferable.
  • the "aromatic hydrocarbon group that may be substituted” shown by R may have an optionally chosen substituent at any possible position, this substituent being exemplified by alkyls having 1 to 3 carbon atoms (e.g., methyl, ethyl, propyl) and halogens.
  • the "aromatic heterocyclic group that may be substituted” shown by R is preferably furyl, thienyl, indolyl, isoindolyl, pyrazinyl, pyridyl, pyrimidinyl, or the like.
  • the "aromatic heterocyclic group that may be substituted" shown by R may have an optionally chosen substituent at any possible position, this substituent being exemplified by alkyls having 1 to 3 carbon atoms (e.g., methyl, ethyl, propyl) and halogens.
  • alkyls having 1 to 3 carbon atoms e.g., methyl, ethyl, propyl
  • halogens e.g., methyl, ethyl, propyl
  • R 9 stands for H, C,_ 10 alkyl, C 2 .
  • alkenyl or an aromatic group more specifically, formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl, crotonyl, 2- cyclohexenecarbonyl or benzoyl, nicotinoyl.
  • the group represented by the formula -S0 2 R 6 is preferably represented by the formula -S0 2 R 6 (R 6 represents an aryl group that may be substituted) .
  • the "aryl group that may be substituted" shown by R is exemplified by phenyl, 1-naphthyl and 2- naphthyl. Said aryl group may have 1 or 2 optionally chosen substituents at any possible positions, these substituents including alkyl groups that may be substituted (e.g., C ⁇ _ 3 alkyls such as methyl, ethyl and propyl) . such alkyl groups may each have 1 or 2 optionally chosen substituents at any possible positions, these substituents including phosphono groups that may be substituted for (e.g., dimethoxyphosphoryl, diethoxyhosphoryl) .
  • R As optionally esterified carboxyl groups shown by R , mention is made of, for example, groups represented by the general formula -C00R 5 [R 5 stands for C ⁇ _ 6 alkyl, C 2 . 6 alkenyl or C 6 _ l0 aralkyl], more specifically, groups formed by combination of carboxyl group with a C ⁇ _ 6 alkyl group, namely, for example, C ⁇ _ 6 alkoxycarbonyl (e.g.
  • C 2 . 6 alkenyloxycarbonyl e.g. allyloxycarbonyl, crotyloxycarbonyl, 2-pentenyloxycarbonyl and 3- hexenyloxycarbonyl
  • aralkyl group namely, for example, C 6 . 10 aralkyloxycarbonyl (e.g. benzyloxycarbonyl and phenethyloxycarbonyl) .
  • the carbon chain of a chain length of 1 to 4 atoms, that may be substituted may be any one, as long as it is a divalent chain whose linear moiety consists of 1 to 4 atoms.
  • Said substituent may be any one, as long as it is capable of binding to the divalent chain constituting the linear moiety.
  • substituents include lower alkyls having 1 to 6 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl), lower (C 3 .
  • cycloalkyls e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl
  • phosphono groups that may be esterified, carboxyl groups that may be esterified and hydroxyl group, with preference given to lower alkyls having 1 to 6 carbon atoms, more preferably Ci. 3 alkyls.
  • Said ester of the carboxyl group that may be esterified is exemplified by those resulting from binding of a carboxyl group and an alkyl group having 1 to 6 carbon atoms, such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert.- butoxycarbonyl, pentyloxycarbonyl and hexyloxycarbonyl.
  • alkyl group having 1 to 6 carbon atoms such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert.- butoxycarbonyl, pentyloxycarbonyl and hexyloxycarbonyl.
  • alkenylene groups e.g. vinylene. propenylene, 1- or 2-butenylene, butadielenylene, 1- methylvinylene, 1-ethylvinylene, 1-propylvinylene, 1- isopropylvinylene, butylvinylene, isobutylvinylene, 1- methylpropanylene, 2-methylpropanylene, 1- ethylpropanylene, 2-propylpropanylene and 1- isopropylpropanylene) , C 2 .
  • alkenylene groups e.g. vinylene. propenylene, 1- or 2-butenylene, butadielenylene, 1- methylvinylene, 1-ethylvinylene, 1-propylvinylene, 1- isopropylvinylene, butylvinylene, isobutylvinylene, 1- methylpropanylene, 2-methylpropanylene, 1- ethylpropanylene, 2-propylpropanylene and 1- isoprop
  • alkynylene groups e.g. ethynylene, 1- or 2-propynylene, 1- or 2-butynylene, methylethynylene, propylethynylene, isobutylethynylene, tert.-butylethynylene, 1-methyl-l-propynylene, 2- methyl-1-propynylene, 3-methyl-2-propynylene, 1-ethyl- 2-propynylene, 1-propyl-2-propynylene and 1-isopropyl- 2-propynylene) .
  • These groups may optionally have 1 to 3 substituents at any possible position.
  • substituents mention is made of similar ones to those exemplified as substituents in the optionally substituted hydrocarbon groups shown by R , R and R .
  • Specific examples of the substituted straight-chain or branched divalent hydrocarbon groups include benzylmethylene, benzylethylene, 1-benzylpropylene, 2- benzylpropylene, 3-indolylmethylmethylene, 3- indolylmethylethylene, l-(3-indolylmethyl)propylene, 2- (3-indolylmethyl)propylene, parahydroxylbenzylmethylene, 4- imidazolylmethylmethylene, methylthioethylmethylene and l-(methylthioethyl)propylene.
  • n is preferably 0.
  • the compound of the present invention is exemplified by the following: •N-valproyl-(L)-valine (lS)-3-forrayl-l-(3- indolylmethyl)-2-propenylamide -N-benzyloxycarbonyl-(L)-alanyl-(L)-alanine (lS)-3- formyl-1-benzyl-2-propenylamide. •N- ⁇ -naphthalenesulfonyl-(L)-isoleucine (lR)-3-formyl- l-(3-indolylmethy1)propylamide
  • the salts of the compounds of general formulas (la) and (I) are preferably physiologically acceptable salts, exemplified by salts with inorganic bases, salts with organic bases, salts with inorganic acids and salts with organic acids, and salts with basic or acidic amino acids.
  • Preferable salts with inorganic bases include alkali metal salts such as sodium salts and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; and aluminum salt.
  • Preferable salts with organic bases include ammonium salt, salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine and N,N'- dibenzylethylene diamine.
  • Preferable salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and phosphoric acid.
  • Preferable salts with organic acids include salts with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzene sulfonic acid and p-toluenesulfonic acid.
  • Preferable salts with basic amino acids include salts with arginine, lysine and ornithine.
  • Preferable salts with acidic amino acids include salts with aspartic acid and glutamic acid.
  • the compound (la) can be produced by allowing a compound represented by the general formula (Ha) R 1 R -Q-NHCH-CHO
  • Q stands for a direct bond or one or two amino acid residual groups which may be substituted;
  • R stands for a hydrogen atom or an optionally substituted hydrocarbon or heterocyclic group; and
  • R stands for an optionally esterified carboxyl group or an acyl group, or a salt thereof, to react, as described below in detail, with an acetaldehdye derivative, followed by, upon necessity, subjecting the reaction mixture to reduction.
  • R -(NHCHCO) n -(NHCHCO) wherein R 1 , R 2 or R 3 independently stand for a hydrogen atom or an optionally substituted hydrocarbon or heterocyclic group; R stands for an optionally esterified carboxyl group or an acyl group; X stands for an optionally substituted straight-chain or branched divalent hydrocarbon group having a chain length of 1 to 4 atoms as the linear moiety; and m and n independently denote 0 or 1, can be produced by allowing a compound represented by the formula (II)
  • Examples of the optionally substituted hydrocarbon group shown by R include C ⁇ _ 4 alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl and isobutyl and C 2 _ 4 lower alkenyl groups such as vinyl, propenyl and butenyl, and these groups may optionally have 1 to 3 substituents on any possible position.
  • substituents mention is made of ones similar to those exemplified as substituents in the optionally substituted hydrocarbon groups shown by R , R and R .
  • As the optionally substituted hydrocarbon groups shown by R 12 mention is made of, among the ones exemplified as R 11 , saturated ones.
  • the compound (1-2) is produced by subjecting the compound (1-1) to reduction.
  • This reduction is conducted, in accordance with a conventional method, in a solvent in the presence of a catalyst under hydrogen atmosphere of 1 to 150 atm.
  • the solvent include alcohols such as methanol, ethanol, propanol, isopropanol and 2-methoxyethanol; aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as ethyl ether, isopropyl ether, dioxane and tetrahydrofuran; halogenated hydrocarbons such as chloroform, dichloromethane and 1,1,2,2- tetrachloroethane; ethyl acetate, acetic acid or suitable mixture of these solvents.
  • reaction temperature ranges from 0 to 100°C, preferably from 10 to 80°C.
  • reaction time ranges from 0.5 to 50 hours.
  • the solvent examples include aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as dioxane, tetrahydrofuran and dimethoxyethane; alcohols such as methanol, ethanol and propanol; N,N-dimethylformamide, dimethyl sulfoxide, chloroform, dichloromethane, 1,2- dichloroethane, 1,1,2,2-tetrachloroethane and suitable mixture of these solvents.
  • the amount of the compound (III) to be employed ranges from 1 to 5 molar equivalents, preferably 1 to 3 molar equivalents, relative to the compound (II). This reaction is conducted at temperatures usually ranging from -50°C to 150°C, preferably from about -10°C to 100°C. The reaction time ranges from 0.5 to 30 hours.
  • This oxidation reaction is conducted in accordance with a per se known oxidation reaction.
  • oxidation using chromic acid such as Jones oxidation using chromium oxide-sulfuric acid-pyridine, Collins oxidation using chromium oxide-pyridine complex, oxidation using pyridinium chlorochromate (PCC) and oxidation using pyridinium dichromate (PDC); oxidation using activated DMSO and oxidation using oxoammonium salt.
  • oxidation is conducted advantageously by activated dimethyl sulfoxide (DMSO) oxidation.
  • DMSO dimethyl sulfoxide
  • the activated DMSO oxidation is conducted in a solvent in the co- presence of DMSO and an electrophilic reagent.
  • the solvent include ethers such as ethyl ether, isopropyl ether, tetrahydrofuran and dioxane; aromatic hydrocarbons such as benzene, toluene and xylene; halogenated hydrocarbons such as N,N- dimethylformamide (DMF), chloroform and dichloromethane; pyridine and dimethyl sulfoxide.
  • DMSO oxidation examples include the dicyclohexylcarbodiimide (DCC) method, the acetic anhydride method, the phosphorus pentoxide method, the chlorine method, the sulfur trioxide-pyridine method, the keteneimine-enamine method and the mercury (II) acetate method, named according to the electrophilic reagent used.
  • DCC dicyclohexylcarbodiimide
  • acetic anhydride method examples include the phosphorus pentoxide method, the chlorine method, the sulfur trioxide-pyridine method, the keteneimine-enamine method and the mercury (II) acetate method, named according to the electrophilic reagent used.
  • This oxidation is advantageously carried out by the sulfur trioxide-pyridine method, in which oxidation is achieved using a sulfur trioxide-pyridine complex as a DMSO activator reagent in the presence of triethylamine.
  • the reaction can also be carried out using dimethyl sulfoxide as a solvent.
  • the amount of triethylamine and sulfur trioxide-pyridine complex to be employed ranges from 1 to 10 molar equivalents, preferably from 2 to 5 molar equivalents, relative to the compound (IV).
  • the reaction temperature ranges from -70 to 80°C, preferably from -20°C to 40°C.
  • the reaction time ranges from 0.5 to 10 hours.
  • the aldehyde derivative (II) thus obtained can be isolated and purified by known means of separation and purification, such as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phasic transfer and chromatography.
  • the compounds (IV) can be produced by, for example, the following method.
  • the compound (V) or its reactive derivative at the carboxyl group or a salt thereof is allowed to react with the compound (VI) or its reactive derivative at the amino group or a salt thereof to yield the compound (IV).
  • Preferable derivatives of the compound (VI) at the amino group thereof include
  • Preferable reactive derivatives of the compound (V) at the carboxyl group thereof include acid halides, acid anhydrides, activated amides and activated esters.
  • the reactive derivatives include acid chlorides; acid azides; mixed acid anhydrides such as those with a substituted phosphoric acid such as dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid or halogenated phosphoric acid, or with dialkylphosphorous acid, sulfurous acid, thiosulfuric acid or sulfuric acid, or with a sulfonic acid such as methanesulfonic acid, or with an aliphatic carboxylic acid such as acetic acid, propionic acid, butyric acid, isobutyropivalic acid, pentanoic acid, isopentanoic acid or trichloroacetic acid or with an aromatic carboxylic acid such as benzoic acid; symmetric acid anhydrides; activated amides with imid
  • reactive derivatives can be optionally chosen depending on the kinds of compound (V) then employed.
  • Preferable salts of reactive derivatives of compound (V) include salts with bases, exemplified by alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, ammonium salt, and organic base salts such as trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt and N,N-dibenzylethylenediamine salt.
  • This reaction is normally carried out in a conventional solvent such as water, alcohol such as methanol and ethanol, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide or pyridine, but can be carried out in any other organic solvent, so long as it does not interfere with the reaction.
  • a conventional solvent such as water, alcohol such as methanol and ethanol, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide or pyridine, but can be carried out in any other organic solvent, so long as it does not interfere with the reaction.
  • a conventional solvent such as water, alcohol such as methanol and ethanol, acetone, dioxane, acetonitrile,
  • this reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N- cyclohexyloxy-N'-(4- diethylaminocyclohexyl)carbodiimide; N,N'- diethylcarbodiimide, N,N'-diisopropylcarbodiimide, N- ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N'- carbonylbis(2-methylimidazole) ; pentamethyleneketene-N- cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-l-
  • This reaction may also be carried out in the presence of an inorganic or organic base such as alkali metal hydrogen carbonate tri(lower)alkylamine, pyridine, N-(lower)- alkylmorpholine or N,N-di(lower)alkylbenzylamine.
  • an inorganic or organic base such as alkali metal hydrogen carbonate tri(lower)alkylamine, pyridine, N-(lower)- alkylmorpholine or N,N-di(lower)alkylbenzylamine.
  • L stands for a carboxy-protecting group, and other symbols are of the same meaning as defined above.
  • the carboxy-protecting group shown by L is exemplified by protecting groups in common use in the field of peptide synthesis, such as ester derivatives.
  • the compound (VII) or its reactive derivative at the carboxyl group or a salt thereof is allowed to react with the compound (VIII) or its reactive derivative at the amino group or a salt thereof to yield the compound (IX), which is then subjected to a deprotection reaction to remove the carboxy-protecting group to yield the compound (V) .
  • the reaction of the compound (VII) or its reactive derivative at the carboxyl group or a salt thereof with the compound (VIII) or its reactive derivative at the amino group or a salt thereof is carried out in substantially the same manner as in Method D.
  • the deprotecting reaction of the compound (IX) to remove its carboxy-protecting group can be conducted by any common method of removing a carboxyl-protecting group, such as deprotection by hydrolysis, reduction or a Lewis acid.
  • the hydrolysis is carried out preferably in the presence of a base or an acid.
  • Preferable bases include inorganic bases such as alkali metal hydroxides (e.g. sodium hydroxide and potassium hydroxide), alkaline earth metal hydroxides (e.g. magnesium hydroxide and calcium hydroxide), alkali metal carbonates (e.g. sodium carbonate and potassium carbonate), alkaline earth metal carbonates (e.g. magnesium carbonate and calcium carbonate), alkali metal hydrogencarbonates (e.g.
  • alkali metal acetates e.g. sodium acetate and potassium acetate
  • alkaline earth metal phosphates e.g. magnesium phosphate and calcium phosphate
  • alkali metal hydrogenphosphates e.g. disodium hydrogenphosphate and dipotassium hydrogenphosphate
  • organic bases such as trialkylamine (e.g. trimethylamine and triethylamine), picoline, N-methylpyrrolidine, N-methylmorpholine, 1,5- diazabicyclo[4.3.0]non-5-ene, 1,4- diazabicyclo[2.2.2]non-5-ene and 1,8- diazabicyclo[5.4.0]-7-undecene.
  • Hydrolysis using a base is often carried out in water or a hydrophilic organic solvent or a mixture of them.
  • Preferable acids include organic acids (e.g. formic acid, hydrobromic acid and sulfuric acid) .
  • This hydrolysis is usually carried out in an organic solvent, water or a mixture of them.
  • Reaction temperature not subject to limitation, is chosen appropriately depending on the kind of carboxy- protecting groups and the method of deptotection then employed.
  • Deprotection using a Lewis acid is carried out by allowing the compound (IX) or a salt thereof to react with a Lewis acid such as a boron trihalide (e.g. boron trichloride and boron trifluoride) , a titanium tetrahalide (e.g. titanium tetrachloride and titanium tetrabromide) , an aluminum trihalide (e.g. aluminum chloride and aluminum bromide), trihaloacetic acid (e.g.
  • a Lewis acid such as a boron trihalide (e.g. boron trichloride and boron trifluoride) , a titanium tetrahalide (e.g. titanium tetrachloride and titanium
  • This deprotecting reaction is preferably carried out in the presence of a cation capturing agent (e.g. anisole and phenol) and usually carried out in a solvent which does not interfere with the reaction, such as a nitroalkane (e.g. nitromethane and nitroethane) , an alkylene halide (e.g. methylene chloride and ethylene chloride), diethyl ether and carbon disulfide. These solvents may be used as a suitable mixture of them.
  • a cation capturing agent e.g. anisole and phenol
  • a solvent which does not interfere with the reaction such as a nitroalkane (e.g. nitromethane and nitroethane) , an alkylene halide (e.g. methylene chloride and ethylene chloride), diethyl ether and carbon disulfide.
  • solvents may be used as a suitable mixture of them.
  • Deprotection by reduction is preferably applied to removing the protecting groups such as esters of haloalkyls (e.g. 2-iodoethyl and 2,2,2-trichloroethyl) and esters of aralkyl (e.g. benzyl).
  • Method of reduction for this deprotection reaction include reduction with a combination of a metal (e.g. zinc and zinc amalgam) or a chromium compound salt (e.g.chromous chloride and chromous acetate) and an organic or inorganic acid (e.g. acetic acid, propionic acid and hydrochloric acid) ; and a conventional catalytic reduction in the presence of a common metal catalyst (e.g. palladium-carbon, Raney nickel).
  • a common metal catalyst e.g. palladium-carbon, Raney nickel
  • the compound (XIII) or a salt thereof is allowed to react with the compound (X) or a salt thereof to yield the compound (XIV), which is then subjected to a deprotecting reaction to remove its carboxyl-protecting group to give the compound (V-2).
  • the reaction of (X) with (XIII) is carried out in an appropriate solvent.
  • This solvent is exemplified by aromatic hydrocarbons such as benzene, toluene and xylene, ethers such as dioxane, tetrahydrofuran and dimethoxyethane, alcohols such as methanol, ethanol and propanol, ethyl acetate, acetonitrile, pyridine, N,N- dimethylformamide, dimethyl sulfoxide, chloroform, dichloromethane, 1,2-dichloroethane, 1,1,2,2- tetrachloroethane, acetone, 2-butanone and a suitable mixture of these solvents.
  • aromatic hydrocarbons such as benzene, toluene and xylene
  • ethers such as dioxane, tetrahydrofuran and dimethoxyethane
  • alcohols such as methanol, ethanol and propanol, ethyl acetate, acetonitrile
  • the reaction of (X) with (XIII) is carried out in the presence of an appropriate base exemplified by alkali metal salts such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate and sodium hydorgencarbonate, amines such as pyridine, triethylamine and N,N-dimethylaniline, sodium hydride and potassium hydride.
  • an appropriate base exemplified by alkali metal salts such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate and sodium hydorgencarbonate, amines such as pyridine, triethylamine and N,N-dimethylaniline, sodium hydride and potassium hydride.
  • the amount of these bases to be employed ranges preferably from about 1 to 5 molar equivalents, relative to the compound (X).
  • This reaction is carried out at temperatures usually ranging from -20 to 150°C, preferably from about -10 to 100°C.
  • the compound (XV) or a salt thereof is allowed to react with the compound (XIII) or a salt thereof to yield the compound (V-2).
  • This sulfonylation is usually carried out under what is called Schotten Baumann's conditions, in which the amino acid derivative (XV), prepared as an aqueous solution of sodium salt thereof, is allowed to react with the compound (XIII), followed by subjecting the reaction mixture to acidification.
  • R 7 NHCO-NHCHCOOL > R 7 NHCO-NHCHCOOH ( XIX ) ( V-5 ) wherein each symbol is of the same meaning as defined above.
  • the compound (X) or a salt thereof is allowed to react with the compound (XVIII) to yield the compound (XIX), which is then subjected to a deprotecting reaction to remove its carboxy-protecting group to give the compound (V-5).
  • the reaction of the compound (X) or a salt thereof with the compound (XVIII) is carried out in an appropriate solvent.
  • This solvent is exemplified by aromatic hydrocarbons such as benzene, toluene and xylene, ethers such as dioxane, tetrahydrofuran and dimethoxyethane, ethyl acetate, acetonitrile, pyridine, N,N-dimethylformamide, chloroform, dichloromethane, 1,2-dichloroethane, 1,1,2,2-tetrachloroethane, acetone, 2-butanone and a suitable mixture of these solvents.
  • the amount of the compound (XVIII) to be employed ranges preferably from about 1 to 5 molar equivalents, relative to the compound (X) .
  • the reaction is conducted usually at temperatures ranging from -20 to 150°C, preferably from about -10 to 100°C.
  • the compound (XIX) thus obtained is subjected to a deprotecting reaction to yield the compound (V-5). This deprotection is carried out in substantially the same manner as in Method E.
  • Method L
  • the compound (X) or a salt thereof is allowed to react with the compound (XX) to yield the compound (XXI), which is then subjected to a deprotecting reaction to remove the carboxy-protecting group to give the compound (V-6).
  • This reaction is carried out in substantially the same manner as in
  • Method K The starting compound (IV) in Method C can also be produced by the following method.
  • M stands for an amino-protecting group, and other symbols are of the same meaning as defined above.
  • the amino-protecting group shown by M is exemplified by protecting groups in common use in the field of peptide synthesis, such as oxycarbonyl derivatives, with preference given to benzyloxycarbonyl.
  • the compound (XXII) or its reactive derivative at the carboxyl group or a salt thereof is allowed to react with the compound (VI) or its reactive derivative at the amino group or a salt thereof to yield the compound (XXIV) , which is then subjected to a deprotecting reaction to remove the amino-protecting group to give the compound (XXV) .
  • reaction of the compound (XXII) or its derivative reactive at the carboxyl group or a salt thereof with the compound (VI) or its derivative reactive at the amino group or a salt thereof is carried out in substantially the same manner as in Method D.
  • the amino-protecting group removing reaction of the compound (XXIV) the amino-protecting group can be removed by any common method employed for the reaction to remove the amino-protecting group.
  • the benzyloxycarbonyl group is removed by catalytic reduction in the presence of a conventional metal catalyst (e.g. palladium-carbon and Raney nickel).
  • Reaction temperature is not subject to limitation, and the reaction is carried out usually under cooling, at room temperature or under warming.
  • the compound (XXV) is acylated in substantially the same manner as in the reaction of the compound (X) with the compound (XI) in Method F or the reaction of the compound (XV) with the compound (XVI) in Method F, sulfonylated in substantially the same manner as in the reaction of the compound (X) with the compound (XIII) in Method G, oxycarbonylated in substantially the same manner as in the reaction of the compound (XV) with the compound (XVII) in Method J, carbamoylated in substantially the same manner as in the reaction of the compound (X) with the compound (XVIII) in Method K, and then thiocarbamoylated in substantially the same manner as in the reaction of the compound (X) with the compound (XX) in Method L, to yield the compound (IV).
  • a portion of the starting compound (IV) of this invention can be produced by, for example, the following method.
  • A stands for a lower alkyl group, and other symbols are of the same meaning as defined above.
  • Examples of the lower alkyl group shown by A include C ⁇ _ 4 ones such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl and sec.-butyl.
  • This reduction can be carried out by a per se known method, for example, reduction by using metal hydride, reduction by using a metal hydride complex compound and reduction by using diborane or a substituted borane.
  • this reaction is carried out by processing the compound (XXVI) with a reducing agent.
  • the reducing agent include metal hydride complex compounds such as alkali metal borohydrides (e.g. sodium borohydride and lithium borohydride) and lithium aluminum hydride and diborane and so on, and the reduction is advantageously carried out by the use of lithium borohydride.
  • This reaction is carried out in an organic solvent which does not interfere with the reaction.
  • the solvent examples include aromatic hydrocarbons such as benzene, toluene and xylene, halogenated hydrocarbons such as chloroform, carbon tetrachloride, dichloromethane, 1,2- dichloroethane and 1,1,2,2-tetrachloroethane, ethers such as diethyl ether, tetrahydrofuran and dioxane, alcohols such as methanol, ethanol, propanol, isopropanol and 2-methoxyethanol, amides such as N,N- dimethylformamide or a suitable mixture of these solvents. From among these solvents, a suitable one is chosen depending on the kind of the reducing agent then employed.
  • the reaction temperature ranges from -20°C to 150°C, especially the range from 0 to 100°C is preferable.
  • the reaction time ranges from about 1 to 24 hours.
  • the starting compound (XXVI) in Method N can be produced by, for example, repeating the following chain-elongation reaction.
  • Method 0
  • This chain-elongation reaction is carried out by a per se known method. More specifically, in this method, a reactive derivative of the compound (XXVII) at the carboxyl group is allowed to react with diazomethane to yield a diazomethylketone derivative, which is then subjected to Wolff Rearrangement in the presence of silver oxide to give the compound (XXVIII).
  • a reactive derivative of the compound (XXVII) at the carboxyl group mention is made of, for example, reactive derivatives described in Method D.
  • the reaction of the reactive derivative of the compound (XXVII) at the carboxyl group with diazomethane is carried out in an inert solvent.
  • the solvent examples include aromatic hydrocarbons such as benzene, toluene and xylene, halogenated hydrocarbons such as chloroform, carbon tetrachloride, dichloromethane, 1,2- dichloroethane and 1,1,2,2-tetrachloroethane, ethers such as diethyl ether, tetrahydrofuran and dioxane, amides such as N,N-dimethylformamide or a suitable mixture of these solvents.
  • aromatic hydrocarbons such as benzene, toluene and xylene
  • halogenated hydrocarbons such as chloroform, carbon tetrachloride, dichloromethane, 1,2- dichloroethane and 1,1,2,2-tetrachloroethane
  • ethers such as diethyl ether, tetrahydrofuran and dioxane
  • amides such as N,N-dimethylformamide or a suitable mixture of these
  • the subsequent Wolff Rearrangement reaction of the diazomethylketone is carried out in an alcoholic solvent, preferably exemplified by methanol, ethanol, propanol, isopropanol, butanol, sec.-butanol and 2- methoxyethanol.
  • an alcoholic solvent preferably exemplified by methanol, ethanol, propanol, isopropanol, butanol, sec.-butanol and 2- methoxyethanol.
  • the compound represented by the formula (la) described above can be produced by a method analogous to that of producing the compound represented by the formula (1-1) or (1-2) described above, in which at least one of m and n denotes 1.
  • the compound represented by the formula (Ha) described above can be produced by a method analogous to that of producing the compound represented by the formula (II) described above, in which at least one of m and n denotes 1.
  • the compound of the formula (la) or (I) can be administered orally or non- orally, as formulated by admixing an effective dose with a physiologically acceptable carrier in the form of solid preparations such as tablets, capsules, granules or powdery compositions; or liquid preparations such as syrup and injectable preparations.
  • Pharmaceutically acceptable carriers are various organic or inorganic carrier substances in common use as pharmaceutical materials, including excipients, lubricants, binders and disintegrating agents for solid preparations, and solvents, solubilizers, suspending agents, isotonizing agents, buffers and soothing agents for liquid preparations.
  • Other pharmaceutical additives such as preservatives, antioxidants, coloring agents and sweetening agents may be used upon necessity.
  • Preferable excipients include lactose, sucrose, D- mannitol, starch, crystalline cellulose and light silicic acid anhydride.
  • Preferable lubricants include magnesium stearate, calcium stearate, talc and colloidal silica.
  • Preferable binders include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose and polyvinylpyrrolidone.
  • Preferable disintegrating agents include starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, cross carmellose sodium and carboxymethyl starch sodium.
  • Preferable solvents include water for injection, alcohol, propylene glycol, macrogol, sesame oil and corn oil.
  • Preferable solubilizers include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, tris-aminomethane, cholesterol, triethanolamine, sodium carbonate and sodium citrate.
  • Preferable suspending agents include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride and monostearic glycerol, and hydrophilic polymers such as polyvinyl alcohol, polyvinyl pyrrolidone, carboxymethyl cellulose sodium, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose and hydroxyproplyl cellulose.
  • Preferable isotonizing agents include sodium chloride, glycerol and D-mannitol.
  • Preferable buffers include buffer solutions of phosphates, acetates, carbonates and citrates.
  • Preferable soothing agents include benzyl alcohol.
  • Preferable preservatives include p-oxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid and sorbic acid.
  • Preferable antioxidants include sulfites and ascorbic acid.
  • cysteine protease which is the subject of this invention, mention is made of protease having thiol group at the center of enzymic activity, which is specifically exemplified by cathepsin L, cathepsin B and carpaine.
  • the compounds of the formulae (la) and (I) possess a strong action of inhibiting cysteine protease and can be safely used with low toxicity.
  • the compounds of the formulae (la) and (I) can be used for the prophylaxis or therapy of diseases (for example, osteoporosis, hypercalcemia, arthrosis such as rheumatoid arthritis, inflammatory, propagation of tumor cells, cancer metastasis, myodystrophy, muscular atrophy, Alzheimer's disease, various autoimmune diseases such as rhematoid arthritis, multiple sclerosis, myathemia gravis, insulin dependent diabetes mellitus (type I diabetes mellitus), inflammatory bowl diseases, systemic lupus erythematosus, glomerulonephritis, autoimmune hemolytic anemia, Hashimoto's disease, idiopathic ulcerative colitis, primary biliary cirrhosis, idiopathic thrombocytopenic purpura, sympathetic ophthalmia, permicious anemia, Sj ⁇ gren's syndrome and Goodpasture's syndrome), in which cysteine protease participate, in mammals (e.
  • the daily dose ranges from about 1 to 1000 mg, preferably from about 10 to 500 mg, depending on patient condition and weight and method of administration, for each adult (weighing 50 kg), in 1 to 3 portions per day, in the case of oral administration. Best Mode for Carrying Out the Invention
  • a purified recombinant human cathepsin L was diluted with a diluent [0.1% Brij 35 (produced by Sigma Chemical Co. ) ] to a concentration of 1 ⁇ g/ml.
  • a diluent [0.1% Brij 35 (produced by Sigma Chemical Co. )
  • One ⁇ l of this enzyme dilution was mixed with 46 ⁇ l of the diluent, 2 ⁇ l of 0.1M DTT and 25 ⁇ l of an activator/buffer (340 mM sodium acetate, 60 mM acetic acid, 4mM disodium EDTA, pH 5.5).
  • a rat cathepsin B was diluted with a diluent [0.1% Brij 35 (produced by Sigma Chemical Co.)] to a concentration of 30 ⁇ g/ml.
  • a diluent [0.1% Brij 35 (produced by Sigma Chemical Co.)] to a concentration of 30 ⁇ g/ml.
  • a diluent [0.1% Brij 35 (produced by Sigma Chemical Co.)] to a concentration of 30 ⁇ g/ml.
  • reaction stopper 100 mM sodium monochloroacetate, 30 mM sodium acetate, pH 4.3
  • reaction was conducted on a 96-well fluoroplate (manufactured by Labo Systems) .
  • Cathepsin L Cathepsin B
  • Bone resorption inhibitory activity was measured by the method of Raisz [Journal of Clinical Investigation, 4_4_, 103-116(1985)]. Specifically, one Sprague-Dawley rat, at 18 days of gestation, was given 50 ⁇ Ci of Ca (calcium isotope, in CaCl 2 solution) by subcutaneous injection. On the following day, the animal was laparotomized and fetal rats were aseptically removed. Both forearm bones (radium and ulna) were cut out from the body of each fetus under an anatomical microscope, and connective tissue and cartilages were removed to the maximum possible extent, to prepare bone culture samples.
  • Ca calcium isotope
  • BGJb medium Fitton-Jackson modification; GIBCO Laboratories, the United States
  • bovine serum albumin final concentration 2 mg/ml
  • N- ⁇ -naphthalenesulfonyl-(L)-isoleucyl-(L)- tryptophan methylester (6.9 g) was dissolved in a mixture of tetrahydrofuran (THF) (40 ml) and methanol (20 ml). To this solution was added dropwise an aqueous solution of potassium hydroxide (1.5 g) under ice-cooling. The mixture was stirred for 20 hours under ice-cooling. The reaction mixture was acidified with 1N-HC1. The organic solvent was distilled off under reduced pressure, and the residue was subjected to extraction with ethyl acetate. The organic layer was washed with brine and dried (MgSO «) .
  • N-(quinoline-2-carbonyl)-(L)- leucyl-(L)-tryptophanol was produced from N- benzyloxycarbonyl-(L)-leucyl-(L)-tryptophanol.
  • N-(pyridine-2-carbonyl)-(L)- isoleucyl-(L)-tryptophanol was produced from N- benzyloxycarbonyl-(L)-isoleucyl-(L)-tryptophanol.
  • N-(quinoline-2-carbonyl)-(L)- tyrosyl-(L)-tryptophanal was produced from N- ( quinoline-2-carbonyl ) - ( L ) -tyrosyl- ( L ) -tryptophanol .
  • N-(quinoline-8-sulfonyl)-(L)- isoleucyl-(L)-tryptophanal was produced from N- (quinoline-8-sulfonyl)-(L)-isoleucyl-(L)-tryptophanol.
  • N-t-Butoxycarbonyl-(L)-phenylalanyl-(L)- tryptophanal 2.4 g
  • formylmethylene triphenylphosphorane 1 g
  • THF tetrahydrofuran
  • toluene 30 ml
  • the solution was stirred for 15 hours at 50°C.
  • the solvent was distilled off, and the residue was subjected to a silica gel column chromatography.
  • N-(2-Benzyl-3-phenylpropionyl)-(L)-tryptophanal (11.5 g) and (formylmethylene)triphenylphosphorane (8.5 g) were dissolved in a mixture of tetrahydrofuran (THF) (10 ml) and toluene (100 ml). The solution was stirred for 13 hours at 55°C. The solvent was distilled off, and the residue was subjected to a silica gel column chromatography. From the fraction eluted with ethyl acetate-hexane (1:2), a pale brown powdery product was obtained. This powdery product was dissolved in ethanol, to which was added Pd-C (10%, 2.0 g) .
  • N- ⁇ -naphthalenesulfonyl-(L)-isoleucine (IS)-3- hydroxy-l-(3-indolylmethyl)propylamide (0.50 g) and triethylamine (0.41 ml) were dissolved in a mixture of dimethyl sulfoxide (2 ml) and dichloromethane (6 ml). To this solution was added, under ice-cooling, a dimethyl sulfoxide solution (2 ml) of a sulfur trioxide-pyridine complex (0.47 g) . The mixture was stirred for 3 hours under ice-cooling.
  • N- ⁇ -naphthalenesulfonyl-(L)-isoleucine (IS)-2- formyl-l-(3-indolylmethyl)ethylamide (0.84 g) and (formylmethylene)triphenylphosphorane (0.61 g) were dissolved in a mixture of tetrahydrofuran (4 ml) and benzene (20 ml). The solution was stirred for 15 hours at 60°C. The solvent was distilled off under reduced pressure. The residue was subjected to a silica gel column chromatography.
  • N- ⁇ -naphthalenesulfonyl-(L)-isoleucine (lR)-4- formyl-1-(3-indolylmethyl)-3-butenylamide (0.42 g) and 5%-palladium carbon (0.30 g) were added to tetrahydrofuran (15 ml). The mixture was hydrogenated under hydrogen atmosphere. The catalyst was filtered off, and the filtrate was concentrated. The residue was subjected to a silica gel column chromatography.
  • N-(quinoline-2-carbonyl)-(L)-tyrosine (lR)-3- formyl-l-(3-indolylmethyl)propylamide was produced by subjecting N-(quinoline-2-carbonyl)-(L)-tyrosine (1S)- 3-formyl-1-(3-indolylmethyl)-2-propenylamide to catalytic hydrogenation.
  • N-(pyridine-2-carbonyl)-(L)-isoleucine (lS)-3- formyl-1-(3-indolylmethyl)-2-propenylamide was produced by reacting N-(pyridine-2-carbonyl)-(L)-isoleucyl-(L)- tryptophanal with (formylmethylene)triphenyl ⁇ phosphorane.
  • N-(quinoline-8-sulfonyl)-(L) -isoleucine (lS)-3- f ormyl-1- ( 3-indolylmethyl) -2-propenylamide was produced by reacting N-(quinoline-8-sulfonyl)-(L)-isoleucyl-(L) - tryptophanal with ( formylmethylene) triphenyl ⁇ phosphorane .
  • N-(quinoline-8-sulfonyl)-(L)-isoleucine (lR)-3- formyl-l-(3-indolylmethyl)propylamide was produced by subjecting N-(quinoline-8-sulfonyl)-(L)-isoleucine
  • a prophylactic or therapeutic apent of the present invention can, for example, be produced with the following formulations:
  • Components (1), (2) and (3) and a half portion of component (4) are mixed and granulated. To these granules, the remaining portion of component (4) is added, and the whole mixture is packed in a gelatin capsule. 2. Tablet
  • the compounds (la) and (I) of this invention have a strong action of inhibiting cysteine protease, they are useful as medicines for prophylaxis and treatment of bone diseases and various diseases caused by abnormal exasperation of cysteine protease.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composé de la formule (Ia'). Dans cette formule, Q' représente un ou deux groupes acides aminés résiduels pouvant être substitués; R1 représente un atome d'hydrogène ou un groupe hydrocarbure ou hétérocyclique facultativement substitué; R4 représente un groupe carboxyle ou un groupe acyle facultativement estérifié; et X représente un groupe hydrocarbure divalent ramifié ou à chaîne linéaire facultativement substitués présentant une longueur de chaîne de 1 à 4 atomes comme fraction linéaire, ou un sel de cette substance, exerçant une puissante activité inhibitrice de la protéase de la cystéine et se révélant utile comme agent prophylactique et thérapeutique contre diverses maladies, notamment les maladies osseuses, causées par un déréglement de la protéase de la cystéine.
PCT/JP1995/001933 1994-09-27 1995-09-25 Derives aldehydes utilises comme inhibiteurs de protease d'upsteine WO1996010014A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU35341/95A AU3534195A (en) 1994-09-27 1995-09-25 Aldehyde derivatives as upsteine protease inhibitors
EP95932228A EP0783489A1 (fr) 1994-09-27 1995-09-25 Derives aldehydes utilises comme inhibiteurs de protease d'upsteine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23183994 1994-09-27
JP6/231839 1994-09-27

Publications (1)

Publication Number Publication Date
WO1996010014A1 true WO1996010014A1 (fr) 1996-04-04

Family

ID=16929824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1995/001933 WO1996010014A1 (fr) 1994-09-27 1995-09-25 Derives aldehydes utilises comme inhibiteurs de protease d'upsteine

Country Status (4)

Country Link
EP (1) EP0783489A1 (fr)
AU (1) AU3534195A (fr)
CA (1) CA2196182A1 (fr)
WO (1) WO1996010014A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0927716A1 (fr) * 1995-10-25 1999-07-07 Senju Pharmaceutical Co., Ltd. Inhibiteurs de la angiogenesis
EP0928786A1 (fr) * 1995-10-25 1999-07-14 Senju Pharmaceutical Co., Ltd. Inhibiteurs da la angiogenesis
US6214800B1 (en) 1995-10-25 2001-04-10 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
US7282512B2 (en) 2002-01-17 2007-10-16 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0128762A2 (fr) * 1983-06-09 1984-12-19 Sankyo Company Limited Peptides ayant une activité hypotensive, leur préparation et utilisation
JPH03258800A (ja) * 1990-03-08 1991-11-19 Taisho Pharmaceut Co Ltd トリペプチド誘導体
EP0611756A2 (fr) * 1993-02-19 1994-08-24 Takeda Chemical Industries, Ltd. Alcool et aldéhyde dérivés comme inhibiteur de cathepsin L et comme inhibiteur de la résorption osseuse

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0128762A2 (fr) * 1983-06-09 1984-12-19 Sankyo Company Limited Peptides ayant une activité hypotensive, leur préparation et utilisation
JPH03258800A (ja) * 1990-03-08 1991-11-19 Taisho Pharmaceut Co Ltd トリペプチド誘導体
EP0611756A2 (fr) * 1993-02-19 1994-08-24 Takeda Chemical Industries, Ltd. Alcool et aldéhyde dérivés comme inhibiteur de cathepsin L et comme inhibiteur de la résorption osseuse

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 116, no. 12, 30 March 1992, Columbus, Ohio, US; abstract no. 129662K, TANAMI,TORU ET AL.: "Preparation of tripeptide aldehyde derivatives as cysteine protease inhibitors" *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0927716A1 (fr) * 1995-10-25 1999-07-07 Senju Pharmaceutical Co., Ltd. Inhibiteurs de la angiogenesis
EP0928786A1 (fr) * 1995-10-25 1999-07-14 Senju Pharmaceutical Co., Ltd. Inhibiteurs da la angiogenesis
US6214800B1 (en) 1995-10-25 2001-04-10 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
US6551999B1 (en) 1995-10-25 2003-04-22 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
US7282512B2 (en) 2002-01-17 2007-10-16 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors

Also Published As

Publication number Publication date
AU3534195A (en) 1996-04-19
CA2196182A1 (fr) 1996-04-04
EP0783489A1 (fr) 1997-07-16

Similar Documents

Publication Publication Date Title
US5498728A (en) Derivatives of L-tryptophanal and their use as medicinals
AU772024B2 (en) Inhibitors of urokinase and blood vessel formation
WO1996016079A2 (fr) Derives d'alpha-cetoamide utilises comme inhibiteurs de cathepsine l
FI112943B (fi) Pyrimidinyylijohdannaisia ja niiden käyttö lääkkeen valmistamiseksi interleukiini proteaasiaktiivisuuden inhiboimiseksi
IE873383L (en) Phosphinic acid derivatives
CZ129694A3 (en) Novel peptide derivatives
KR20000035925A (ko) 매트릭스 메탈로프로테아제 저해제인 포스핀산 아미드
CA2302467A1 (fr) Secretagogues d'hormone de croissance
CA2300848A1 (fr) Traitement de l'insuffisance cardiaque congestive avec des secretagogues d'hormone de croissance
EP0743319B1 (fr) Composés benzo-condensés d'azépinone et pipéridinone, utile comme inhibiteurs de l'ACE et du NEP
CA2126687A1 (fr) Derives de substitution peptidyliques renfermant de l'acide phosphonique, agents antidegeneratifs
IE53076B1 (en) Amido-amino acids
EP2021334A1 (fr) Synthèse et utilisations de dérivés d'acide pyroglutamique
EP0641800B1 (fr) Dérivés du lactol comme inhibiteurs de la cathépsine L
WO1996010014A1 (fr) Derives aldehydes utilises comme inhibiteurs de protease d'upsteine
EP0731107A1 (fr) Préparation de dérivés d'aldéhydes
JPH08208462A (ja) カテプシンｌ阻害剤
JPH08104685A (ja) ラクトール誘導体、その製造法および用途
US6649593B1 (en) Modulators of SREBP processing
JPH08151355A (ja) アシルアミノアルデヒド誘導体およびその用途
CN116986985A (zh) 查尔酮类衍生物及其应用
JPH08283221A (ja) アルデヒド誘導体の製造法

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 1995 545586

Country of ref document: US

Date of ref document: 19951101

Kind code of ref document: A

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2196182

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995932228

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995932228

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995932228

Country of ref document: EP